去势抵抗性前列腺癌化疗耐药机制的研究进展  

Research advance in chemoresistance mechanisms of castration resistant prostate cancer

作　　者：胡斐[1] 朱雅慧 许青[1] 

机构地区：[1]同济大学附属上海市第十人民医院肿瘤科,上海200072

出　　处：《现代肿瘤医学》2015年第21期3194-3196,共3页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:81372749)

摘　　要：前列腺癌的发病率和死亡率逐年上升,去势治疗是中晚期前列腺癌的最主要治疗方法,但去势抵抗性前列腺癌为临床治疗难点,化疗虽为后续主要治疗手段,但易出现耐药。最新研究表明,去势抵抗性前列腺癌患者化疗后再使用抗雄激素药物能提高总生存率。本文就近年来去势抵抗性前列腺癌化疗耐药相关机制做一综述,探讨雄激素受体、自噬、JAK/STAT3信号通路在去势抵抗性前列腺癌发生化疗耐药过程中所发挥的调控作用。In recent few years the morbidity and mortality of prostate cancer show an increasing trend, endocrine therapy remains the mainstay of treatment, but the castration resistant prostate cancer（CRPC） after endocrine therapy become difficulty to conquer. Although chemotherapy is the main treatment for CRPC, patients with continuing chemo- therapy may prone to chemoresistance. The new researches show the overall survival rate of CRPC could be improved while using the antiandrogen drugs after chemotherapy. We review the mechanisms of chemoresistance for CRPC, to investigate the regulation of androgen receptor, autophagy, and JAK/STAT3 signal pathway during the process of the-moresistance.

关 键 词：去势抵抗性前列腺癌 化疗耐药 雄激素受体 自噬 JAK/STAT3通路 

分 类 号：R737.25[医药卫生—肿瘤]